AxoGen Profile

50.50
USD 1.00  2.02%
100%
81%

Exercise or conversion by Robert Rudelius of 12000 shares of AxoGen subject to Rule 16b-3

AxoGen insider trading alert for exercise of director stock option (right to purchase) by Robert Rudelius, the corporate stakeholder, on June 12, 2018. This event was filed by Axogen Inc with SEC on 2018-06-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

AxoGen Summary

AxoGen (AXGN) is traded on Nasdaq Capital Markets in USA. It is located in FLORIDA, U.S.A and employs 184 people. AxoGen is listed under Medical Equipment category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.91 B. AxoGen conducts business under Healthcare sector and is part of Medical Equipment industry. This company has 38.15 M outstanding shares of which 975.73 K shares are presently shorted by private and institutional investors with about 4.01 trading days to cover. AXOGEN INC currently holds about 36.51 M in cash with (9.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06.
Check AxoGen Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 50.5HorizonTargetOdds Above 50.5
87.82%30 days 50.50 12.07%
Based on normal probability distribution, the odds of AxoGen to move above current price in 30 days from now is about 12.07% (This AxoGen probability density function shows the probability of AxoGen Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Essex Woodlands Health Ventures IncCommon Shares3.7 M135.5 M
Blackrock IncCommon Shares2.1 M75.2 M
View AxoGen Diagnostics

Selected AxoGen Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

AxoGen Against Markets

Risk Adjusted
Performance Score (0 to 100)
22 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for AxoGen are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen operates under Medical Devices classification in USA and traded on Nasdaq Capital Markets. It employs 184 people. more
Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
NameAxoGen
CEO and President and DirectorKaren ZaderejView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationFLORIDA, U.S.A
Business Address13631 Progress Boulevard
ExchangeNasdaq Capital Markets
CIK Number00805928.0
CUSIP05463X106
SectorHealthcare
IndustryMedical Equipment
BenchmarkDOW
Websitewww.axogeninc.com
Contact Number386 462 6800
CurrencyUSD - US Dollar

Recommendations

AxoGen Analyst Recommendations
Target PriceAdvice# of Analysts
8.92Buy3Odds
AxoGen current and past analyst recommendations published by number of research institutions as well as average analyst consensus
AxoGen Analyst Advice  

Earnings

AxoGen Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.1February 22, 2017
AxoGen normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

AxoGen Corporate Directors
Robert Rudelius Independent Director
Amy Wendell Director
Joseph Mandato Independent Director
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.